Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
about
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapyBIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
P2860
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Select clinical trials of erlo ...... mphasis on phase III outcomes.
@ast
Select clinical trials of erlo ...... mphasis on phase III outcomes.
@en
type
label
Select clinical trials of erlo ...... mphasis on phase III outcomes.
@ast
Select clinical trials of erlo ...... mphasis on phase III outcomes.
@en
prefLabel
Select clinical trials of erlo ...... mphasis on phase III outcomes.
@ast
Select clinical trials of erlo ...... mphasis on phase III outcomes.
@en
P356
P1433
P1476
Select clinical trials of erlo ...... emphasis on phase III outcomes
@en
P2093
Alan B Sandler
L Minerva Burgos Fuster
P356
10.3816/CLC.2004.S.011
P407
P478
P577
2004-12-01T00:00:00Z